ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Faculty Opinions recommendation of Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.734027977.793562867
◽
2019
◽
Cited By ~ 1
Author(s):
Sherene Loi
Keyword(s):
Breast Cancer
◽
Clinical Outcomes
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Phase 1
◽
Phase 1 Study
Download Full-text
Related Documents
Cited By
References
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer
Breast Cancer Research and Treatment
◽
10.1007/s10549-018-4813-z
◽
2018
◽
Vol 171
(1)
◽
pp. 111-120
◽
Cited By ~ 12
Author(s):
Aditya Bardia
◽
Ayca Gucalp
◽
Noashir DaCosta
◽
Nashat Gabrail
◽
Michael Danso
◽
...
Keyword(s):
Breast Cancer
◽
Estrogen Receptor
◽
Androgen Receptor
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Phase 1
◽
Phase 1 Study
◽
Estrogen Receptor Positive
◽
Receptor Inhibitor
Download Full-text
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
JAMA Oncology
◽
10.1001/jamaoncol.2018.4224
◽
2019
◽
Vol 5
(1)
◽
pp. 74
◽
Cited By ~ 148
Author(s):
Leisha A. Emens
◽
Cristina Cruz
◽
Joseph Paul Eder
◽
Fadi Braiteh
◽
Cathie Chung
◽
...
Keyword(s):
Breast Cancer
◽
Clinical Outcomes
◽
Triple Negative Breast Cancer
◽
Triple Negative
Download Full-text
Abstract PD3-13: Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer
10.1158/1538-7445.sabcs17-pd3-13
◽
2018
◽
Cited By ~ 1
Author(s):
K Kalinsky
◽
JJ Harding
◽
A DeMichele
◽
JR Infante
◽
K Gogineni
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Phase 1
◽
Phase 1 Study
Download Full-text
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).
Journal of Clinical Oncology
◽
10.1200/jco.2016.34.15_suppl.1011
◽
2016
◽
Vol 34
(15_suppl)
◽
pp. 1011-1011
◽
Cited By ~ 3
Author(s):
Angela DeMichele
◽
James J. Harding
◽
Melinda L. Telli
◽
Pamela N. Munster
◽
Rana McKay
◽
...
Keyword(s):
Breast Cancer
◽
Small Molecule
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Phase 1
◽
Small Molecule Inhibitor
◽
Phase 1 Study
◽
Molecule Inhibitor
Download Full-text
Abstract P6-18-35: A phase 1 study of erlotinib and metformin in advanced triple negative breast cancer
10.1158/1538-7445.sabcs18-p6-18-35
◽
2019
◽
Author(s):
KM Fenn
◽
MA Maurer
◽
SM Lee
◽
KD Crew
◽
MS Trivedi
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Phase 1
◽
Phase 1 Study
Download Full-text
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer
Investigational New Drugs
◽
10.1007/s10637-015-0244-4
◽
2015
◽
Vol 33
(4)
◽
pp. 890-894
◽
Cited By ~ 33
Author(s):
Zahi Mitri
◽
Cansu Karakas
◽
Caimiao Wei
◽
Brian Briones
◽
Holly Simmons
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Phase 1
◽
Cdk Inhibitor
◽
Phase 1 Study
Download Full-text
Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer
Clinical Breast Cancer
◽
10.1016/j.clbc.2019.08.004
◽
2020
◽
Vol 20
(1)
◽
pp. 80-86
Author(s):
Kathleen Fenn
◽
Matthew Maurer
◽
Shing M. Lee
◽
Katherine D. Crew
◽
Meghna S. Trivedi
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Phase 1
◽
Phase 1 Study
Download Full-text
Comparative Study for Clinical Outcomes of Triple-Positive and Triple-Negative Breast Cancer: Long-term Results in 161 Patients Followed in a Single Center
Journal of Breast Disease
◽
10.14449/jbd.2020.8.1.78
◽
2020
◽
Vol 8
(1)
◽
pp. 78-84
Author(s):
Seungyeol Baeg
◽
Inseok Park
◽
Jungbin Kim
◽
Chansub Park
◽
Hyunjin Cho
◽
...
Keyword(s):
Breast Cancer
◽
Comparative Study
◽
Clinical Outcomes
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Long Term Results
◽
Single Center
Download Full-text
Abstract P6-13-21: Phase 1 study of GR antagonist mifepristone (M) in combination with eribulin (E) in advanced solid tumors, with dose expansion in patients (pts) with GR-positive triple-negative breast cancer (TNBC)
10.1158/1538-7445.sabcs15-p6-13-21
◽
2016
◽
Author(s):
S Wilks
◽
M Modiano
◽
A Spira
◽
C Becerra
◽
J Walling
◽
...
Keyword(s):
Breast Cancer
◽
Solid Tumors
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Phase 1
◽
Advanced Solid Tumors
◽
Phase 1 Study
Download Full-text
Mifepristone (MIFE), a glucocorticoid receptor (GR) antagonist, in combination with eribulin (E) in advanced solid tumors: A phase 1 study with dose expansion in patients (pts) with triple-negative breast cancer (TNBC).
Journal of Clinical Oncology
◽
10.1200/jco.2015.33.15_suppl.e12070
◽
2015
◽
Vol 33
(15_suppl)
◽
pp. e12070-e12070
◽
Cited By ~ 1
Author(s):
Rita Nanda
◽
Sharon Wilks
◽
Manuel R. Modiano
◽
Alexander I. Spira
◽
Carlos Becerra
◽
...
Keyword(s):
Breast Cancer
◽
Glucocorticoid Receptor
◽
Solid Tumors
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Phase 1
◽
Advanced Solid Tumors
◽
Phase 1 Study
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close